Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review

• Published in: Endocrine Connections Vol. 9; no. 10; pp. R207 - R228
• Main Authors: Stelmachowska-Banaś, Maria, Czajka-Oraniec, Izabella
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 01.10.2020; Bioscientifica
• Subjects: adrenal insufficiency; ctla-4; diabetes mellitus; hypoparathyroidism; hypophysitis; immune checkpoint inhibitors; immunotherapy; pd-1; pd-l1; Review; thyroid disorders; adrenal insufficiency; immunotherapy; thyroid disorders; PD-L1; CTLA-4; hypophysitis; diabetes mellitus; hypoparathyroidism; immune checkpoint inhibitors; PD-1

Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-cell proteins involved in the activation of immune response toward malignancies. Their introduction into clinical practice was a milestone in modern cancer treatment. However, the significant advantage of ICIs...